<SEC-DOCUMENT>0001214659-25-016274.txt : 20251112
<SEC-HEADER>0001214659-25-016274.hdr.sgml : 20251112
<ACCEPTANCE-DATETIME>20251112093420
ACCESSION NUMBER:		0001214659-25-016274
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20251103
FILED AS OF DATE:		20251112
DATE AS OF CHANGE:		20251112

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Davis Matthew W.
		CENTRAL INDEX KEY:			0002094283
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38599
		FILM NUMBER:		251469903

	MAIL ADDRESS:	
		STREET 1:		C/O AQUESTIVE THERAPEUTICS
		STREET 2:		30 TECHNOLOGY DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aquestive Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001398733
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				208623253
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		30 TECHNOLOGY DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059
		BUSINESS PHONE:		908-941-1900

	MAIL ADDRESS:	
		STREET 1:		30 TECHNOLOGY DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MonoSol Rx, Inc.
		DATE OF NAME CHANGE:	20070507
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>marketforms-71181.xml
<DESCRIPTION>PRIMARY DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2025-11-03</periodOfReport>

    <noSecuritiesOwned>1</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001398733</issuerCik>
        <issuerName>Aquestive Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>AQST</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0002094283</rptOwnerCik>
            <rptOwnerName>Davis Matthew W.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O AQUESTIVE THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>30 TECHNOLOGY DRIVE</rptOwnerStreet2>
            <rptOwnerCity>WARREN</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07059</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>false</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>Chief Development Officer</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable></nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes></footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Lori Braender, as Attorney-In-Fact</signatureName>
        <signatureDate>2025-11-12</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>poa.htm
<DESCRIPTION>POA DOCUMENT
<TEXT>
<html>
  <body>
    <pre>
      POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints
each of Lori J. Braender, Ellen S. Knarr and Christopher M. Rogers, signing
singly, the undersigned's true and lawful attorney-in-fact to:
(1)	prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the United States Securities and Exchange Commission (the "SEC") a
Form ID, including amendments thereto, or any other documents necessary or
appropriate to obtain codes and passwords enabling the undersigned to make
electronic filings with the SEC of reports required by Section 16(a) of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), Rule 144 under
the Securities Act of 1933, as amended ("Rule 144"), or any rule or regulation
of the SEC via the Electronic Data Gathering and Retrieval ("EDGAR") system and
legally bind the undersigned for purpose of the Form ID or such other documents;
(2)	act as an account administrator for the undersigned's EDGAR account,
including
(i)	appointing, removing and replacing account administrators, technical
administrators, account users, and delegated entities; (ii) maintaining the
security of the undersigned's EDGAR account, including modification of access
codes;
(iii) maintaining, modifying and certifying the accuracy of information on the
undersigned's EDGAR account dashboard; and (iv) taking any other actions
contemplated by Rule 10 of Regulation S-T;
(3)	prepare, execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer of Aquestive Therapeutics, Inc., a Delaware corporation
(the "Company"), Forms 3, 4, and 5, and Forms 144,, each including amendments
thereto, in accordance with Section 16(a) of the Exchange Act and the rules
thereunder and Rule 144, respectively;
(4)	do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form ID,
including amendments thereto, or Form 3, 4, or 5, or Form 144, and timely file
such form with the SEC and any stock exchange or similar authority; and
(5)	take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in the
discretion of such attorney-in-fact.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes

as the undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5, and Form 144, with
respect to the undersigned's holdings of and transactions in securities issued
by the Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this   day of October, 2025.

 I	/vl.D
MATTHEW DAVIS, M.r5.





I CERTIFY that on this*d:)"-A..day of October, 2025, MATTHEW DAVIS, M.D.
personally appeared before me and acknowledged under oath, to my satisfaction,
that HE:
Is named in and personally signed the above document. STATE OF PENNSYLVANIA









Notary Public Printed Name

Notary Public Date of Expiration



2
    </pre>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
